Recruiting

MEASUREMENT OF CIRCULATING MUTATION BURDEN

Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer

ClinicalTrials.gov IDNCT06792721

PhaseNot Applicable

Enrollment30

SponsorCentre Francois Baclesse

Age30 Years – 50 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Carcinoma, Genetic Predisposition to Cancer, BRCA Mutation, cfMB, Mutation Burden

About this study

Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer

Interventions

Genetic: Mutation Burden cfMB analysis — Blood samples will be collected (one time only)

Primary outcomes

Comparing the mutational burden in a person genetically predisposed to cancer with that of a non-predisposed relative (At the enrollment in the study (one point))

Eligibility information

Inclusion Criteria: * Female participant * Participant undergoing oncogenetic follow-up at the Centre François Baclesse * Participant belonging to a pair of related biological siblings * Within the sibling pair, one participant is a carrier of a hereditary predisposition linked to a BRCA1/2 mutation (case), and the other participant is not a carrier (control). * Participant between 30 and 50 years of age * Participant affiliated to a social security scheme * Participant having given her consent to participate by signing an informed consent form prior to any specific study-related procedure. Exclusion Criteria: \-

Study locations

Centre François Baclesse, Caen, France France

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-22.